P3 Health Partners Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 79/100
What the filing says
P3 Health Partners Inc. (market cap ~$39.1M) issued a Securities Purchase Agreement on September 8, 2026, with VBC Growth SPV 7, LLC (managed by Chicago Pacific entities) committing up to $70,000,000 aggregate. The company is issuing Series D-1 19.5% Cumulative Preferred Stock (1.1M shares authorized at $100 stated value per share = $110M cap) plus warrants exercisable for 0.66333% of outstanding Class A and Class V common stock per $1M invested, 7-year term, at Nasdaq Minimum Price. Preferred carries liquidation preference of $100/share plus accrued dividends, senior to common but junior to debt. Holders receive board representation (1 seat), governance rights, information/operating review rights, and registration rights for warrant-exercise shares via shelf registration (must be effective within 90 days or face 1% monthly liquidated damages up to 5% cap). Standstill provisions restrict CPF from exceeding 49.99% ownership through December 31, 2027.
Why this rating
Deal size ($70M max) is ~179% of company's $39.1M market cap — transformational dilution and control shift. High 19.5% preferred dividend rate and liquidation preference heavily favor investors. Governance rights and standstill to 2027 materially constrain management. Significant though not going-concern-level event.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.